Generic Blow Looms For Lundbeck
Executive Summary
With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
You may also be interested in...
Lundbeck Launches Rexulti In Europe, Phase II LU AF11167 Trial In Schizophrenia
Danish CNS specialist begins Rexulti roll-out in Europe and proof-of-concept study of its early pipeline candidate Lu AF11167.
Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments
Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.
Lundbeck's Rexulti Growth Hopes Clouded By Dementia Agitation Data Setback
Denmark-based Lundbeck's plans to make Rexulti the first approved drug for agitation associated with dementia have been knocked back by mixed clinical data, necessitating another Phase III trial.